{"id":831249,"date":"2025-03-28T16:52:25","date_gmt":"2025-03-28T20:52:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/"},"modified":"2025-03-28T16:52:25","modified_gmt":"2025-03-28T20:52:25","slug":"curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/","title":{"rendered":"Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">LEXINGTON, Mass.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 28, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on <span class=\"xn-chron\">Monday, March 31, 2025<\/span>, at <span class=\"xn-chron\">8:00 a.m. ET<\/span>. Management will host a conference call and simultaneous webcast on the same day at <span class=\"xn-chron\">8:30 a.m. ET<\/span>.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/607886\/Curis_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/607886\/Curis_Logo.jpg\" title=\"(PRNewsfoto\/Curis, Inc.)\" alt=\"(PRNewsfoto\/Curis, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Participants may join by dialing (800)-836-8184 from\u00a0the United States\u00a0or (646)-357-8785 from other locations\u00a0or a live audio webcast can be accessed <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4394145-1&amp;h=1922803793&amp;u=https%3A%2F%2Finvestors.curis.com%2Fevents-and-presentations&amp;a=here\" target=\"_blank\" rel=\"nofollow\">here<\/a>\u00a0from the investor section of the Curis website. A replay of the conference call will be available at <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4394145-1&amp;h=3498758698&amp;u=http%3A%2F%2Fwww.curis.com%2F&amp;a=www.curis.com\" target=\"_blank\" rel=\"nofollow\">www.curis.com<\/a>.<\/p>\n<p>\n        <b>About Curis, Inc.<br \/><\/b>Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the Phase 1\/2 TakeAim Lymphoma study (CA-4948-101)\u00a0in patients with relapsed\/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1\/2 TakeAim Leukemia study (CA-4948-102) in patients with relapsed\/refractory acute myeloid leukemia (AML) and relapsed\/refractory high risk myelodysplastic syndrome (hrMDS), and as a frontline combination therapy with venetoclax and azacitidine in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL.\u00a0Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge\u00ae to Genentech, a member of the Roche Group, under which they are commercializing Erivedge\u00ae for the treatment of advanced basal cell carcinoma. For more information, visit Curis&#8217;s website at <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4394145-1&amp;h=3498758698&amp;u=http%3A%2F%2Fwww.curis.com%2F&amp;a=www.curis.com\" target=\"_blank\" rel=\"nofollow\">www.curis.com<\/a>.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE52801&amp;sd=2025-03-28\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025-302414676.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025-302414676.html<\/a><\/p>\n<p>SOURCE  Curis, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE52801&amp;Transmission_Id=202503281607PR_NEWS_USPR_____NE52801&amp;DateId=20250328\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire LEXINGTON, Mass. , March 28, 2025 \/PRNewswire\/ &#8212; Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from\u00a0the United States\u00a0or (646)-357-8785 from other locations\u00a0or a live audio webcast can be accessed here\u00a0from the investor section of the Curis website. A replay of the conference call will be available at www.curis.com. About Curis, Inc.Curis is a biotechnology company focused on &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-831249","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire LEXINGTON, Mass. , March 28, 2025 \/PRNewswire\/ &#8212; Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from\u00a0the United States\u00a0or (646)-357-8785 from other locations\u00a0or a live audio webcast can be accessed here\u00a0from the investor section of the Curis website. A replay of the conference call will be available at www.curis.com. About Curis, Inc.Curis is a biotechnology company focused on &hellip; Continue reading &quot;Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-28T20:52:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/607886\/Curis_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025\",\"datePublished\":\"2025-03-28T20:52:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\\\/\"},\"wordCount\":328,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/607886\\\/Curis_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\\\/\",\"name\":\"Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/607886\\\/Curis_Logo.jpg\",\"datePublished\":\"2025-03-28T20:52:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/607886\\\/Curis_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/607886\\\/Curis_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/","og_locale":"en_US","og_type":"article","og_title":"Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 - Market Newsdesk","og_description":"PR Newswire LEXINGTON, Mass. , March 28, 2025 \/PRNewswire\/ &#8212; Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from\u00a0the United States\u00a0or (646)-357-8785 from other locations\u00a0or a live audio webcast can be accessed here\u00a0from the investor section of the Curis website. A replay of the conference call will be available at www.curis.com. About Curis, Inc.Curis is a biotechnology company focused on &hellip; Continue reading \"Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-28T20:52:25+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/607886\/Curis_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025","datePublished":"2025-03-28T20:52:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/"},"wordCount":328,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/607886\/Curis_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/","name":"Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/607886\/Curis_Logo.jpg","datePublished":"2025-03-28T20:52:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/607886\/Curis_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/607886\/Curis_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/curis-to-report-fourth-quarter-2024-financial-and-operating-results-and-host-conference-call-and-webcast-on-march-31-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=831249"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831249\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=831249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=831249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=831249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}